Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer

Ads

You May Also Like

Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company

Horizon Discovery Enters into License Agreement with US Immuno-Oncology Company Horizon out-licenses proprietary cell ...

Achillion to Present at Two Upcoming Investor Conferences

NEW HAVEN, Conn., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced ...